Jeff Johnson
Stock Analyst at Baird
(4.49)
# 274
Out of 5,241 analysts
157
Total ratings
51.4%
Success rate
25.62%
Average return
Main Sectors:
Stocks Rated by Jeff Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVST Envista Holdings | Maintains: Outperform | $30 → $31 | $23.05 | +34.49% | 11 | May 7, 2026 | |
| INMD InMode | Maintains: Neutral | $17 → $14 | $13.97 | +0.21% | 5 | May 7, 2026 | |
| ALC Alcon | Maintains: Outperform | $98 → $90 | $66.28 | +35.79% | 12 | May 7, 2026 | |
| HSIC Henry Schein | Upgrades: Outperform | $78 → $100 | $72.92 | +37.14% | 11 | Feb 23, 2026 | |
| BBNX Beta Bionics | Maintains: Neutral | $28 → $14 | $9.42 | +48.62% | 3 | Feb 18, 2026 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $18 → $30 | $13.86 | +116.45% | 17 | Dec 16, 2025 | |
| ZBH Zimmer Biomet Holdings | Downgrades: Neutral | $117 → $100 | $86.08 | +16.17% | 15 | Dec 16, 2025 | |
| COO The Cooper Companies | Maintains: Outperform | $85 → $98 | $61.45 | +59.48% | 19 | Dec 5, 2025 | |
| DXCM DexCom | Maintains: Outperform | $112 → $90 | $66.95 | +34.43% | 15 | Sep 26, 2025 | |
| SYK Stryker | Maintains: Outperform | $378 → $405 | $317.75 | +27.46% | 11 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $325 → $276 | $155.16 | +77.88% | 18 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $180 → $238 | $154.61 | +53.94% | 12 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $70 | $25.76 | +171.74% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $67 | $9.74 | +587.89% | 6 | Feb 18, 2022 |
Envista Holdings
May 7, 2026
Maintains: Outperform
Price Target: $30 → $31
Current: $23.05
Upside: +34.49%
InMode
May 7, 2026
Maintains: Neutral
Price Target: $17 → $14
Current: $13.97
Upside: +0.21%
Alcon
May 7, 2026
Maintains: Outperform
Price Target: $98 → $90
Current: $66.28
Upside: +35.79%
Henry Schein
Feb 23, 2026
Upgrades: Outperform
Price Target: $78 → $100
Current: $72.92
Upside: +37.14%
Beta Bionics
Feb 18, 2026
Maintains: Neutral
Price Target: $28 → $14
Current: $9.42
Upside: +48.62%
Tandem Diabetes Care
Dec 16, 2025
Upgrades: Outperform
Price Target: $18 → $30
Current: $13.86
Upside: +116.45%
Zimmer Biomet Holdings
Dec 16, 2025
Downgrades: Neutral
Price Target: $117 → $100
Current: $86.08
Upside: +16.17%
The Cooper Companies
Dec 5, 2025
Maintains: Outperform
Price Target: $85 → $98
Current: $61.45
Upside: +59.48%
DexCom
Sep 26, 2025
Maintains: Outperform
Price Target: $112 → $90
Current: $66.95
Upside: +34.43%
Stryker
Oct 30, 2024
Maintains: Outperform
Price Target: $378 → $405
Current: $317.75
Upside: +27.46%
Oct 24, 2024
Maintains: Outperform
Price Target: $325 → $276
Current: $155.16
Upside: +77.88%
Dec 21, 2023
Upgrades: Outperform
Price Target: $180 → $238
Current: $154.61
Upside: +53.94%
Aug 4, 2023
Maintains: Outperform
Price Target: $67 → $70
Current: $25.76
Upside: +171.74%
Feb 18, 2022
Maintains: Outperform
Price Target: $78 → $67
Current: $9.74
Upside: +587.89%